Table 1.

Cutaneous manifestations following COVID-19 vaccines in Iran

Case no	Type of disorder	Age	Gender	Comorbidity	COVID-19 test/history	Vaccine type	Time of incidence	Ref.
1	Extensive rash and edema	77	Female	Hypertension	Negative	ChAdOx1-S	2 days after the 1st dose	[20]
2	Radiation Recall Dermatitis	50	Female	History of breast cancer and radical mastectomy	Not stated	BBIBP-CorV	1 week after the 2nd dose	[21]
3	Erythemato-violaceous and sclerotic lesions	70	Female	-	Negative	ChAdOx1-S	2 days after the 1st dose	[22]
4	Panniculitis	40	Female	-	Not stated	Sputnik V	13 days after the 1st dose	[23]
5	Alopecia areata	23	Female	-	Not stated	ChAdOx1-S	1 week after the 1st dose	[24]
6		74	Male	Fatty liver	Not stated	BBIBP–CorV	2 days after the 2nd dose	[25]
7		37	Male	-	Not stated	BBIBP–CorV	6 days after the both doses	[25]
8	Herpes simplex	63	Female	Rheumatoid arthritis	Not stated	BBIBP–CorV	7 days after the 2nd dose	[26]
9	Toxic Epidermal Necrolysis (TEN)	76	Male	Atorvastatin 10 mg/day taken for several years	Not stated	BBIBP–CorV	1 day after vaccination	[27]
10		71	Male	–	Not stated	BBIBP–CorV	10 days after the 1st dose	[25]
11	Pemphigus vulgaris (PV)	76	Female	Diabetes mellitus, hyperlipidemia, and ischemic heart disease	Not stated	BBIBP–CorV	1 month after the 2nd dose	[28]
12		30	Female	–	Not stated	BBIBP–CorV	16 days after 1st dose	[25]
13	New-onset lichen planus (LP)	52	Female	–	Positive	BBIBP–CorV	1 week after the 2nd dose	[29]
14		45	Female	Hypertension	Not stated	BBIBP–CorV	14 days after the 1st dose	[25]
15		40	Male	–	Not stated	BBIBP–CorV	10 days after the both	[25]
16		45	Male	–	Not stated	BBIBP–CorV	7 days after the both	[25]
17		45	Male	–	Not stated	ChAdOx1-S	7 days after the 1st dose	[25]
18		49	Female	–	Not stated	BBIBP–CorV	10 days after the 1st dose	[25]
19	Psoriasis exacerbation	50	Male	Arthritis	Not stated	BBIBP–CorV	4 days after the first dose, 6 days after the 2nd dose	[25]
20	Bullous pemphigoid	85	Female	–	Not stated	BBIBP–CorV	20 days after the 1st dose	[25]
21		91	Male	–	Not stated	BBIBP–CorV	19 days after the 1st dose	[25]
22	Cutaneous vasculitis	45	Male	–	Not stated	BBIBP–CorV	2 days after the 1st dose	[25]
23	Pityriasis rosea	26	Male	Hypertension, diabetes mellitus	Not stated	BBIBP–CorV	14 days after the booster	[25]
24	Herpes zoster	60	Female	–	Not stated	BBIBP–CorV	6 days after the 1st dose	[25]
25	Urticaria and erythema multiform	31	Male	–	Not stated	BBIBP–CorV	11 days after the 2nd dose	[25]
26		32	Female	–	Not stated	ChAdOx1-S	20 days after the 1st	[25]
27	Morphea	35	Female	Hyperlipidemia, diabetes	Not stated	ChAdOx1-S	10 days after the 1st	[25]
28	Steven–Johnson syndrome	63	Female	Mild plaque-type psoriasis type II diabetes mellitus	Not stated	BBIBP–CorV	24h after vaccination	[30]